Ovid Therapeutics Inc. — fact timeline

Ovid Therapeutics Inc. shareholders approved Ratification of KPMG LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-06-10 meeting.

“Proposal 3 : The Company’s stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026 by the votes set forth in the table below: For Against Abstain Broker Non-Votes 130,845,667 32,505 80,756 N/A”

Ovid Therapeutics Inc. shareholders approved Advisory vote on compensation paid to named executive officers at the 2026-06-10 meeting.

“Proposal 2: The Company’s stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers, as disclosed in the Proxy Statement, by the votes set forth in the table below: For Against Abstain Broker Non-Votes 84,511,953 8,901,691 2,334,071 35,211,213”

Ovid Therapeutics Inc. shareholders approved Election of director Jeremy M. Levin, DPhil, MB BChir for a three-year term at the 2026-06-10 meeting.

“Proposal 1 : The Company’s stockholders elected the nominee for director to serve a three-year term until the Company’s 2029 annual meeting of stockholders and until his successor has been duly elected and qualified, or, if sooner, until his death, resignation or removal, by the votes set forth in the table below: Nominee For Withheld Broker Non-Votes Jeremy M. Levin, DPhil, MB BChir 87,219,707 8,528,008 35,211,213”

Anna Greka was appointed as Class III director at Ovid Therapeutics Inc..

“On May 29, 2026, the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “Company”) approved, effective as of June 15, 2026, an increase in the size of the Board and, upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), the appointment of Anna Greka, M.D., Ph.D., as a Class III director of the Company, with her term expiring at the Company’s 2029 annual meeting of stockholders.”

Ovid Therapeutics Inc. reported financial results for first quarter ended March 31, 2026.

“On May 12, 2026, Ovid Therapeutics Inc. (the “Company”) issued a press release announcing business updates and first quarter 2026 financial results.”

Ovid Therapeutics Inc. issued 10,701,710 pre-funded warrants of warrant to the Investors for purchase price of $2.009 per Pre-Funded Warrant.

“On March 17, 2026, Ovid Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”), pursuant to which the Company agreed to issue and sell an aggregate of 19,154,321 shares (the “Shares”) of its common stock, par value $0.001 per share (“Common Stock”), at a purchase price of $2.01 per share and, in lieu of Common Stock, pre-funded warrants to purchase up to 10,701,710 shares of Common Stock (the “Pre-Funded Warrants” and, together with the Shares, the “Securities”) at a purchase price of $2.009 per Pre-Funded Warrant, to the Investors in a private placement (the “PIPE financing”).”

Ovid Therapeutics Inc. issued 19,154,321 shares of common stock of common stock to the Investors for purchase price of $2.01 per share.

“On March 17, 2026, Ovid Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”), pursuant to which the Company agreed to issue and sell an aggregate of 19,154,321 shares (the “Shares”) of its common stock, par value $0.001 per share (“Common Stock”), at a purchase price of $2.01 per share and, in lieu of Common Stock, pre-funded warrants to purchase up to 10,701,710 shares of Common Stock (the “Pre-Funded Warrants” and, together with the Shares, the “Securities”) at a purchase price of $2.009 per Pre-Funded Warrant, to the Investors in a private placement (the “PIPE financing”).”

Ovid Therapeutics Inc. entered into Securities Purchase Agreement with the purchasers named therein valued at $60.0 million (effective 2026-03-17).

“On March 17, 2026, Ovid Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”), pursuant to which the Company agreed to issue and sell an aggregate of 19,154,321 shares (the “Shares”) of its common stock, par value $0.001 per share (“Common Stock”), at a purchase price of $2.01 per share”

Ovid Therapeutics Inc. issued to purchase 28,861,000 shares of Common Stock of warrant to the Investors (including the Chief Executive Officer) for $1,400.00 per Security.

“purchase) and a Series B Warrant to purchase 500 shares of Common Stock and/or Pre-Funded Warrants (together, a “Security”). The Securities will be sold at a purchase price of $1,400.00 per Security to the Investors, which includes the Company’s Chief Executive Officer. The Warrants will each have an exercise price of $1.40 per share. The PIPE financing is”

Ovid Therapeutics Inc. issued to purchase 38,481,325 shares of Common Stock of warrant to the Investors (including the Chief Executive Officer) for $1,400.00 per Security.

“purchase) and a Series B Warrant to purchase 500 shares of Common Stock and/or Pre-Funded Warrants (together, a “Security”). The Securities will be sold at a purchase price of $1,400.00 per Security to the Investors, which includes the Company’s Chief Executive Officer. The Warrants will each have an exercise price of $1.40 per share. The PIPE financing is”

Ovid Therapeutics Inc. issued 57,722 shares of preferred stock to the Investors (including the Chief Executive Officer) for $1,400.00 per Security.

“purchase) and a Series B Warrant to purchase 500 shares of Common Stock and/or Pre-Funded Warrants (together, a “Security”). The Securities will be sold at a purchase price of $1,400.00 per Security to the Investors, which includes the Company’s Chief Executive Officer. The Warrants will each have an exercise price of $1.40 per share. The PIPE financing is”

Ovid Therapeutics Inc.: Filed Certificate of Designation establishing Series B Convertible Preferred Stock designating 57,722 shares of preferred stock (effective 2025-10-03).

“On October 3, 2025, the Company filed the Certificate of Designation with the Delaware Secretary of State designating 57,722 shares of its authorized and unissued preferred stock as Series B Preferred Stock.”

Ovid Therapeutics Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“August 12, 2025, that the Company’s application to transfer to the Nasdaq Capital Market was approved and the Company is eligible for an additional 180 calendar day period, or until February 9, 2026 (the “Second Compliance Date”), to regain compliance with the minimum bid price requirement. At the opening of business on August 14, 2025, the Company’s common stock will be transferred to the Nasdaq Capital Market, which operates in substantially the same manner as the Nasdaq Global Select Market, where it continues to trade under the symbol “OVID.” The Company intends to monitor the closing bid”

Stelios Papadopoulos was appointed as Class I director at Ovid Therapeutics Inc..

“On March 1, 2025, the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “Company”) increased the size of the Board from five to six directors and appointed Stelios Papadopoulos, Ph.D., as a Class I director of the Company”

Ovid Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“February 10, 2025, Ovid Therapeutics Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the average closing bid price of the Company’s shares of common stock was below the minimum closing bid price of $1.00 per share during the last 31 consecutive trading days (the “Notice”), as required for continued listing on the Nasdaq under Rule 5450(a)(1) of the Nasdaq’s Listing Rules (the “Rules”). The Notice has no immediate impact on the listing of the Company’s common stock, which w”

Ovid Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“February 10, 2025, Ovid Therapeutics Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the average”

Margaret "Meg" Alexander was appointed as President and Chief Operating Officer at Ovid Therapeutics Inc..

“On September 8, 2024, the Board of Directors of Ovid Therapeutics Inc. (the “Company”) appointed Margaret “Meg” Alexander, the Company’s Chief Strategy Officer, to President and Chief Operating Officer (“COO”) of the Company, effective September 9, 2024.”

Thomas Perone departed as General Counsel, Chief Compliance Officer and Corporate Secretary at Ovid Therapeutics Inc..

“On June 27, 2024, Ovid Therapeutics Inc. (the “Company”) announced that Thomas Perone, the Company’s former General Counsel, Chief Compliance Officer and Corporate Secretary, would be departing from the Company in those roles, effective as of July 11, 2024 (the “Separation Date”) in connection with a workforce reduction.”

Ovid Therapeutics Inc. announced a restructuring with charges of approximately $4.0 million (17 people, or approximately 43% of the Company's existing headcount).

“of a general release of claims against the Company. The Company anticipates a one-time severance-related charge associated with the workforce reduction to be approximately $4.0 million, which represents cash expenditures related to employee severance and notice period payments, benefits and related costs that the Company expects to incur in connection with the”

Jason Tardio departed as Chief Operating Officer at Ovid Therapeutics Inc..

“Jason Tardio will cease serving as the Company’s Chief Operating Officer.”

Thomas Perone departed as General Counsel, Chief Compliance Officer and Corporate Secretary at Ovid Therapeutics Inc..

“on the Separation Date, Thomas Perone will cease serving as the Company’s General Counsel, Chief Compliance Officer and Corporate Secretary”

Ovid Therapeutics Inc. reported financial results for the first quarter ended March 31, 2024.

“Ovid Therapeutics Inc. (the "Company") issued a press release announcing Business Update, First Quarter 2024 Financial Results.”

Ovid Therapeutics Inc. reported financial results for the fourth quarter and year ended December 31, 2023.

“Ovid Therapeutics Inc. (the “Company”) issued a press release announcing Business Update, Fourth Quarter and Full Year 2023 Financial Results”

Ovid Therapeutics Inc. reported financial results for the third quarter ended September 30, 2023.

“On November 3, 2023, Ovid Therapeutics Inc. (the “Company”) issued a press release announcing Third Quarter 2023 Financial Results and Corporate Updates.”

Ovid Therapeutics Inc. entered into Purchase Agreement with Ligand Pharmaceuticals Incorporated valued at $30 million (effective 2023-10-17).

“On October 17, 2023, Ovid Therapeutics Inc. (the “Company”) entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Ligand Pharmaceuticals Incorporated (“Ligand”) for the sale to Ligand of the following (the “Purchased Assets”):”

Ovid Therapeutics Inc. reported financial results for second quarter ended June 30, 2023.

“On August 4, 2023, Ovid Therapeutics Inc. (the “Company”) issued a press release announcing Second Quarter 2023 Financial Results and Corporate Updates.”

Ovid Therapeutics Inc. shareholders approved Ratification of the selection of KPMG LLP as the independent registered public accounting firm at the 2023-06-08 meeting.

“Proposal 4 : The Company’s stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023 by the votes set forth in the table below: For Against Abstain 61,226,349 65,728 2,922”

Ovid Therapeutics Inc. shareholders approved Advisory vote on the frequency of future advisory votes on executive compensation at the 2023-06-08 meeting.

“Proposal 3 : The Company’s stockholders recommended, on an advisory basis, a frequency of “one year” for the advisory vote to approve the compensation paid to the Company’s named executive officers by the votes set forth in the table below: One Year Two Year Three Year Abstain Broker Non-Votes 44,015,622 11,727 793,928 14,642 16,459,080”

Ovid Therapeutics Inc. shareholders approved Advisory vote to approve the compensation paid to the Company's named executive officers at the 2023-06-08 meeting.

“Proposal 2 : The Company’s stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers, as disclosed in the Proxy Statement, by the votes set forth in the table below: For Against Abstain Broker Non-Votes 44,681,350 113,666 40,903 16,459,080”

Ovid Therapeutics Inc. shareholders approved Election of Directors at the 2023-06-08 meeting.

“Proposal 1 : The Company’s stockholders elected all of the nominees for director to serve a three-year term until the Company’s 2026 annual meeting of stockholders, or until their respective successors are duly elected and qualified, by the votes set forth in the table below: Nominee For Withheld Broker Non-Votes Karen Bernstein 39,704,019 5,131,900 16,459,080 Jeremy M. Levin 44,455,812 380,107 16,459,080”

Ovid Therapeutics Inc. reported financial results for the first quarter ended March 31, 2023.

“On May 5, 2023, Ovid Therapeutics Inc. (the “Company”) issued a press release announcing First Quarter 2023 Financial Results and Corporate Updates.”

Ovid Therapeutics Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $46,280 for the fourth quarter and $1.5 million for the year ended December 31, 2022.

“Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022.”

Ovid Therapeutics Inc. reported financial results for third quarter ended September 30, 2022.

“On November 8, 2022 , Ovid Therapeutics Inc. (the “Company”) issued a press release announcing Third Quarter 2022 Financial Results and Corporate Highlights.”

Dr. Kevin Fitzgerald was appointed as director at Ovid Therapeutics Inc..

“On October 6, 2021, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “Company”), the Board appointed Dr. Kevin Fitzgerald, Ph.D. as a director of the Company, effective immediately.”

Robert Michael Poole was appointed as Class I director at Ovid Therapeutics Inc..

“the Board appointed Dr. Robert Michael Poole as a Class I director of the Company, effective July 9, 2021”

Jeremy M. Levin was appointed as President at Ovid Therapeutics Inc..

“the Company’s Board of Directors (the “Board”) appointed Dr. Jeremy M. Levin as President of the Company, in addition to his current duties as Chairman of the Board and Chief Executive Officer of the Company, effective upon the Officer Resignation.”

Dr. Amit Rakhit resigned as President and Chief Medical Officer at Ovid Therapeutics Inc..

“Dr. Amit Rakhit, President and Chief Medical Officer of Ovid Therapeutics Inc. (the “Company”), notified the Company of his resignation from such positions with the Company effective August 27, 2021”